Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Michael Lübbert, Claudia Schmoor, Anne Hagemeijer, Björn Hackanson, Rainer Claus, Björn Rüter, Mathias Schmid, Ulrich Germing, MD, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, MD, Uwe Platzbecker, MD, Oliver Galm, Wolfram Brugger, Gerhard Heil, Pierre W. Wijermans, Konstanze Döhner, Hartmut Döhner

Blood (2011) 118 (21): 2609.

https://doi.org/10.1182/blood.V118.21.2609.2609

Published: 2011

Journal Articles

Epigenetic Dysregulation of the Tissue Inhibitor of Metalloproteinases-2 Gene in Multiple Myeloma

Oliver Galm, Edgar Jost, MD, Claudia Schubert, James G. Herman, MD, Tim H Brümmendorf, Stefan Wilop, MD

Blood (2011) 118 (21): 5089.

https://doi.org/10.1182/blood.V118.21.5089.5089

Published: 2011

Journal Articles

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Michael Lubbert, Claudia Schmoor, Björn Rüter, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Rainer Claus, Barbara Deschler, Björn W. Hackanson, Konstanze Döhner, Pierre Wijermans, Hartmut Döhner

Blood (2010) 116 (21): 2185.

https://doi.org/10.1182/blood.V116.21.2185.2185

Published: 2010

Journal Articles

Epigenetic Downregulation of Secreted Frizzled-Related Proteins In Philadelphia Positive and Philadelphia Negative Myeloproliferative Neoplasms

Karla Bennemann, MD, Claudia Schubert, Stefan Wilop, MD, Tim H. Brummendorf, MD, Oliver Galm, MD, Edgar Jost, MD

Blood (2010) 116 (21): 4647.

https://doi.org/10.1182/blood.V116.21.4647.4647

Published: 2010

Journal Articles

Friday leukemia: myth or reality?

Stefan Wilop, Oliver Galm, Laura Thompson, Rainhardt Osieka, Tim H. Brummendorf, Edgar Jost

Blood (2010) 115 (4): 912.

https://doi.org/10.1182/blood-2009-11-255240

Published: 2010

Journal Articles

Synergistic Induction of Cell Death and Apoptosis by the Histone Deacetylase Inhibitor SAHA (Vorinostat) and the Demethylating Agent DAC in Multiple Myeloma.

Edgar Jost, Claudia Schubert, Tim Bruemmendorf, MD, Oliver Galm

Blood (2009) 114 (22): 2393.

https://doi.org/10.1182/blood.V114.22.2393.2393

Published: 2009

Journal Articles

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Tim H Brummendorf, MD, Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost, Oliver Galm, Carsten Bokemeyer, MD, Tessa Holyoake, Stefan Balabanov

Blood (2009) 114 (22): 1724.

https://doi.org/10.1182/blood.V114.22.1724.1724

Published: 2009

Journal Articles

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, Björn H. Rüter, Mathias Schmid, Rainer Claus, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner

Blood (2009) 114 (22): 4141.

https://doi.org/10.1182/blood.V114.22.4141.4141

Published: 2009

Journal Articles

Progressive Chromatin Repression and Promoter Methylation of a -catenin Correlates with AML Transformation in Patients with and without 5q Deletions.

Michael McDevitt, MD, PhD, Ying Ye, MD, Mingzhou Guo, Hetty E. Carraway, MD, Oliver Galm, Judith E. Karp, Steven D. Gore, MD, Jaroslaw Maciejewski, Jeanne Kowalski, Xiao-Fei Wang, B. Douglas Smith, MD, James G. Herman, MD

Blood (2008) 112 (11): 3369.

https://doi.org/10.1182/blood.V112.11.3369.3369

Published: 2008

Journal Articles

Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial

Michael Lübbert, Mathias Schmid, Björn Rüter, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner

Blood (2008) 112 (11): 2965.

https://doi.org/10.1182/blood.V112.11.2965.2965

Published: 2008

Journal Articles

a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.

Ying Ye, Michael McDevitt, Mingzhou Guo, Judith E. Karp, Steve Gore, Hetty Carraway, Xiaofei Wang, Oliver Galm, Jaroslaw Maciejewski, Andrew Dunbar, Lukasz Gondek, Doug B. Smith, Steve Allen, Craig Hooker, James G. Herman

Blood (2007) 110 (11): 2119.

https://doi.org/10.1182/blood.V110.11.2119.2119

Published: 2007

Journal Articles

Epigenetic Inactivation of the Secreted Frizzled-Related Protein Gene Family in Multiple Myeloma.

Edgar Jost, MD, Deniz Gezer, Stefan Wilop, MD, James G. Herman, MD, Rainhardt Osieka, MD, Oliver Galm, MD

Blood (2007) 110 (11): 2131.

https://doi.org/10.1182/blood.V110.11.2131.2131

Published: 2007

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, MD, Björn Rüter, MD, Rainer Claus, MD, Mathias Schmid, MD, Ulrich Germing, MD, Hartmut Eimermacher, MD, Arnold Ganser, MD, Uwe Platzbecker, MD, Oliver Galm, MD, Wolfram Brugger, MD, Gerhard Heil, MD, Pierre W. Wijermans, MD, Dietmar Pfeifer, PhD, Claudia Schmoor, PhD, Hartmut Döhner, MD

Blood (2007) 110 (11): 300.

https://doi.org/10.1182/blood.V110.11.300.300

Published: 2007

Journal Articles

Aberrant DNA Methylation of the C/EBPalpha Promoter Region in Hematopoietic Malignancies.

Edgar Jost, MD, Nicole do, James G. Herman, MD, Rainhardt Osieka, MD, Oliver Galm, MD

Blood (2005) 106 (11): 4236.

https://doi.org/10.1182/blood.V106.11.4236.4236

Published: 2005

Journal Articles

Aberrant DNA Methylation Patterns in Chronic Idiopathic Myelofibrosis.

Edgar Jost, M.D., Gerald Gehbauer, M.D., Christoph E. Maintz, M.D., Peter Jousten, M.D., Leo Habets, M.D., James G. Herman, M.D., Rainhardt Osieka, M.D., Oliver Galm, M.D.

Blood (2004) 104 (11): 2443.

https://doi.org/10.1182/blood.V104.11.2443.2443

Published: 2004

Journal Articles

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

Oliver Galm, Hirohide Yoshikawa, Manel Esteller, Rainhardt Osieka, James G. Herman

Blood (2003) 101 (7): 2784–2788.

https://doi.org/10.1182/blood-2002-06-1735

Published: 2003

NARROW

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Epigenetic Dysregulation of the Tissue Inhibitor of Metalloproteinases-2 Gene in Multiple Myeloma

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Epigenetic Downregulation of Secreted Frizzled-Related Proteins In Philadelphia Positive and Philadelphia Negative Myeloproliferative Neoplasms

Friday leukemia: myth or reality?

Synergistic Induction of Cell Death and Apoptosis by the Histone Deacetylase Inhibitor SAHA (Vorinostat) and the Demethylating Agent DAC in Multiple Myeloma.

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Progressive Chromatin Repression and Promoter Methylation of a -catenin Correlates with AML Transformation in Patients with and without 5q Deletions.

Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial

a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.

Epigenetic Inactivation of the Secreted Frizzled-Related Protein Gene Family in Multiple Myeloma.

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.

Aberrant DNA Methylation of the C/EBPalpha Promoter Region in Hematopoietic Malignancies.

Aberrant DNA Methylation Patterns in Chronic Idiopathic Myelofibrosis.

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only